Fundraising Fox株式会社HikariQ Health
Tokyo, JP · 1 known investors
Find your way into 株式会社HikariQ Health
Sign up to see every warm intro you have to 株式会社HikariQ Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 株式会社HikariQ Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HikariQ Health develops innovative immunoassay methods and antibody therapeutics using proprietary Q-body technology, a fluorescence quenching-based antibody modification technique. The company targets pharmaceutical and medical applications to improve healthcare diagnostics and therapeutics globally.
Also known as HikariQ · HikariQ Health
Founders & leadership
Investors · 1
How we know: Coral Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Company profile
researched Aug 2026株式会社HikariQ Health (HikariQ) is a Tokyo-based biotechnology venture built around "Q-body," an antibody modification technology in which dyes or drugs are embedded inside the antibody structure. The technology originates from the research group of Professor Hiroshi Ueda at the Institute of Innovative Research, Tokyo Institute of Technology, and is based on a fluorescence quenching phenomenon identified by that group. The company positions itself as a university-originated startup pursuing two application tracks: immunoassay methods and antibody therapeutics.
In immunoassays, Q-body is described as adding a rapid, simple biosensing function that enables a single-step "mix with antigen only" measurement without a wash step, with expected benefits in speed, sensitivity and precision. Although the technology was originally developed for immunoassay use, the company states it is also researching application to antibody drugs, where the aim is added safety. HikariQ describes its intent to apply the technology beyond the medical industry to a range of other fields.
Founding story
HikariQ was established in 2021 as a biotechnology venture to develop innovative immunoassay methods and antibody therapeutics using its proprietary Q-body antibody modification technology. The underlying technique derives from a fluorescence quenching phenomenon discovered by the research group of Professor Hiroshi Ueda at the Institute of Innovative Research, Tokyo Institute of Technology, making the company a Tokyo Tech spinout.
▸Full profile — market position, technology, go-to-market, geography
Market position
A research-stage, university-originated biotechnology venture whose differentiation rests on the Q-body antibody modification platform for wash-free, single-step immunoassays and for antibody therapeutics.
Technology
Q-body is an antibody engineering approach in which fluorescent dyes or drug payloads are embedded within the antibody itself. It relies on a fluorescence quenching phenomenon: for measurement applications, the modified antibody acts as a biosensor whose signal responds on antigen binding, allowing a one-step assay in which sample and reagent are simply mixed and no wash step is required. The company also reports research into using the same embedding approach for antibody drugs, with safety as the intended added property.
Go-to-market
The company publicly solicits investors and co-development partners to advance its business, indicating a partnership- and collaboration-led approach to commercializing the Q-body platform.
Pharmaceutical and medical applications are the primary focus, with the company also stating an intent to apply the technology in fields beyond the medical industry. It is additionally seeking investors and joint development partners.
Geography
Headquartered in Tokyo, Japan, with technology origins at the Tokyo Institute of Technology; the company states an ambition to contribute to society across various fields.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 1
launches, deals, and filingsHikariQ was founded in 2021 to develop innovative immunoassay methods and antibody therapeutics using its proprietary Q-body antibody modification technology.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- 株式会社HikariQ Healthhikariq.co.jp · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 株式会社HikariQ Health do?
- Tokyo Tech spinout developing Q-body antibody-engineering technology for immunoassays and antibody drugs.
- Who founded 株式会社HikariQ Health?
- 株式会社HikariQ Health was founded by 吉井康祐.
- Who are 株式会社HikariQ Health's investors?
- 株式会社HikariQ Health's investors include Coral Capital.
- Where is 株式会社HikariQ Health headquartered?
- 株式会社HikariQ Health is headquartered in Tokyo, JP.